Autoimmune Neuromuscular Disorders
Kyverna Therapeutics Inc. focuses on generalized myasthenia gravis, myasthenia gravis, and stiff person syndrome, with clinical interest centered on immune-mediated weakness, neuromuscular transmission disorders, and related autoimmune disease mechanisms.
- Generalized myasthenia gravis
- Myasthenia gravis
- Stiff person syndrome
The sponsor also studies CD19-directed cell therapy approaches in these conditions, reflecting a therapeutic emphasis on refractory neuromuscular autoimmunity.
Inflammatory Kidney Disease
Another major area of interest is lupus nephritis, where the clinical program addresses immune-driven renal inflammation and the management of severe systemic lupus erythematosus-related kidney involvement.
- Lupus nephritis
Research in this area is aligned with immune reconstitution strategies for difficult-to-treat renal autoimmune disease.
Systemic Autoimmune Disease
Kyverna Therapeutics Inc. is active in broader systemic autoimmune disease research, including systemic sclerosis and rheumatoid arthritis, with attention to multi-organ inflammatory involvement and persistent immune dysregulation.
- Systemic sclerosis
- Rheumatoid arthritis
These programs indicate a therapeutic focus on complex autoimmune conditions that affect connective tissue, joints, and internal organs.
Neuroimmunology and Demyelinating Disease
The sponsor also studies primary progressive multiple sclerosis and secondary progressive multiple sclerosis, supporting research in chronic neuroinflammatory and demyelinating disease settings.
- Primary progressive multiple sclerosis
- Secondary progressive multiple sclerosis
This area reflects interest in progressive neurological disability associated with persistent immune-mediated damage in the central nervous system.
